180 Wealth Advisors’s Fortress Biotech FBIO Stock Holding History

180 Wealth Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$188K	Sell	61,600 -2,200	-3%	-$5.67K	0.02%	468
2026 Q1	$178K	Sell	63,800 -12,050	-16%	-$41K	0.02%	451
2025 Q4	$278K	Sell	75,850 -6,650	-8%	-$18.9K	0.03%	381
2025 Q3	$305K	Sell	82,500 -10,550	-11%	-$26.7K	0.04%	356
2025 Q2	$173K	Buy	93,050 +5,600	+6%	+$9.7K	0.02%	403
2025 Q1	$136K	Buy	87,450 +6,150	+8%	+$10.8K	0.02%	391
2024 Q4	$165K	Buy	81,300 +13,000	+19%	+$23.6K	0.03%	401
2024 Q3	$98.7K	Buy	68,300 +5,950	+10%	+$11.3K	0.02%	434
2024 Q2	$123K	Buy	+62,350	New	+$113K	0.02%	414

Other funds holding FBIO

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

180 Wealth Advisors's FBIO Position: Q2 2026 in Review

180 Wealth Advisors reduced its Fortress Biotech (FBIO) stake by 3.4% in Q2 2026, selling an estimated $5.67K and leaving 61,600 shares worth $188K. The position accounts for 0.02% of the portfolio, ranked #468.

180 Wealth Advisors first reported a position in FBIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $305K in Q3 2025. 55 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.

180 Wealth Advisors held 61,600 shares of Fortress Biotech worth $188K as of Q2 2026.
180 Wealth Advisors sold 2,200 Fortress Biotech shares in Q2 2026, an estimated $5.67K.
Fortress Biotech made up 0.02% of 180 Wealth Advisors's portfolio in Q2 2026, its #468 holding.
180 Wealth Advisors first reported a position in Fortress Biotech in Q2 2024 and has held it in 9 quarters since.
180 Wealth Advisors's Fortress Biotech position peaked at $305K in Q3 2025.
55 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.